Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
AI-Driven Growth | Explore Certara's strategic investments in artificial intelligence and new software releases, positioning the company at the forefront of biosimulation innovation |
Cloud Platform Vision | Delve into Certara's ambitious development of a comprehensive Cloud platform, aiming to revolutionize clinical trial software integration and efficiency |
Market Challenges | Uncover the complexities Certara faces in its regulatory services segment and the impact on overall growth projections, with analysts targeting $12.00 |
Financial Landscape | Examine Certara's financial performance, including a 14% revenue increase and healthy gross profit margins, amid a cautious market outlook |
Metrics to compare | CERT | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship RelationshipCERTPeersSector | |
---|---|---|---|---|
P/E Ratio | −656.4x | −1.2x | −0.5x | |
PEG Ratio | −6.61 | −0.01 | 0.00 | |
Price/Book | 1.6x | 1.0x | 2.6x | |
Price / LTM Sales | 4.4x | 1.7x | 3.2x | |
Upside (Analyst Target) | 47.9% | 13.1% | 42.7% | |
Fair Value Upside | Unlock | 10.7% | 5.8% | Unlock |